NCT05868499View on ClinicalTrials.gov

Rollover Study From EXG-US-01

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 30, 2027

Study Completion Date

January 30, 2027

Conditions
Telomere Biology Disorders With Bone Marrow Failure
Interventions
BIOLOGICAL

EXG34217

Single infusion

Trial Locations (1)

45229

Cincinnati Children's Hospital, Cincinnati

Sponsors
All Listed Sponsors
lead

Elixirgen Therapeutics, Inc.

INDUSTRY

NCT05868499 - Rollover Study From EXG-US-01 | Biotech Hunter | Biotech Hunter